Intraindividual comparison of two extracorporeal LDL apheresis methods: Lipidfiltration and HELP

被引:37
作者
Julius, U
Metzler, W
Pietzsch, J
Fassbender, T
Klingel, R
机构
[1] Univ Hosp Carl Gustav Carus, Inst Clin Metab Res, D-01307 Dresden, Germany
[2] Apheresis Res Inst, Cologne, Germany
关键词
LDL apheresis; lipidfiltration; double filtration plasmapheresis; membrane differential filtration; fibrinogen; hypercholesterolemia; coronary artery disease; low-density lipoprotein cholesterol; hemorheology;
D O I
10.1177/039139880202501210
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Low density lipoprotein (LDL) apheresis is an effective treatment option for patients with severe hypercholesterolemia not adequately responding to diet and drug therapy. Membrane differential filtration (MDF), synonymous with double filtration plasmapheresis (DFPP), here named Lipidfiltration, and heparin-induced extracorporeal LDL-precipitation (HELP) are two of the five methods available for extracorporeal LDL apheresis. In this prospective investigation 6 patients with severe LDL-hypercholesterolemia and CAD were treated in a cross-over design with Lipidfiltration at two stages of technical development and HELP to compare the efficacy of these two LDL apheresis methods with respect to lowering and modifying plasma lipids and rheologically relevant plasma proteins, especially fibrinogen. In total, 44 LDL apheresis sessions were investigated. In weekly intervals, patients were treated with consecutive LDL apheresis sessions with either Lipidfiltration and HELP, treating identical plasma volumes. In one part of the investigation Lipidfiltration was performed with the novel Lipidfilter EC-50, combined with a newly developed blood and plasma therapy machine allowing optimized plasma heating. The results showed that the reduction rates of LDL-cholesterol, lipoprotein(a) and triglycerides were essentially identical for both methods. Also pretreatment levels of total cholesterol, triglycerides, LDL-cholesterol and HDL-cholesterol were not significantly different in both treatment groups. Both methods lead to a significant reduction of serum lipoproteins, especially for LDL-cholesterol, which was decreased by 61.4% with Lipidfiltration (treated plasma volume: 2998 ml) and 61.3% with HELP (treated plasma volume: 3013 ml). With respect to Lipidfiltration LDL-cholesterol reduction was more efficient with the novel Lipidfilter EC-50. Mean pretreatment HDL cholesterol concentrations remained unchanged. Comparing Cascadeflo AC-1770 with the novel Lipidfilter EC-50 reduction rates of HDL-cholesterol (17.4% versus 6.4%) and total protein (17.9% versus 7.8%) were significantly reduced. Lipidfiltration and HELP both resulted in a reduction of plasma viscosity and hemorheologically relevant plasma proteins, like fibrinogen.
引用
收藏
页码:1180 / 1188
页数:9
相关论文
共 42 条
  • [1] Bosch T, 1999, Ther Apher, V3, P209
  • [2] REGRESSION OF CORONARY-ARTERY DISEASE AS A RESULT OF INTENSIVE LIPID-LOWERING THERAPY IN MEN WITH HIGH-LEVELS OF APOLIPOPROTEIN-B
    BROWN, G
    ALBERS, JJ
    FISHER, LD
    SCHAEFER, SM
    LIN, JT
    KAPLAN, C
    ZHAO, XQ
    BISSON, BD
    FITZPATRICK, VF
    DODGE, HT
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (19) : 1289 - 1298
  • [3] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [4] Low-density lipoprotein (LDL) oxidizability before and after LDL apheresis
    Donner, MG
    Parhofer, KG
    Richter, WO
    Schwandt, P
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1999, 48 (07): : 881 - 886
  • [5] Dräger LJ, 1998, EUR J CLIN INVEST, V28, P994
  • [6] FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
  • [7] Geiss H C, 1999, Ther Apher, V3, P199, DOI 10.1046/j.1526-0968.1999.00157.x
  • [8] GODEHARDT E, 1993, TREATMENT OF SEVERE DYSLIPOPROTEINEMIA IN THE PREVENTION OF CORONARY HEART DISEASE 4, P208
  • [9] Evidence for maximal treatment of atherosclerosis: Drastic reduction of cholesterol and fibrinogen restores vascular homeostasis
    Jaeger, BR
    [J]. THERAPEUTIC APHERESIS, 2001, 5 (03): : 207 - 211
  • [10] Jansen M, 2000, WIEN KLIN WOCHENSCHR, V112, P61